CA2957005C — High-purity quinoline derivative and method for manufacturing same
Assigned to Eisai R&D Management Co Ltd · Expires 2021-10-12 · 5y expired
What this patent protects
Provided is a quinoline derivative compound represented by fommla (IV) or a salt thereof, for example, a methanesulfonate salt, wherein the content of the compound represented by fommla (I) is 350 ppm by mass or less, and methods for producing a compound represented by formula (I…
USPTO Abstract
Provided is a quinoline derivative compound represented by fommla (IV) or a salt thereof, for example, a methanesulfonate salt, wherein the content of the compound represented by fommla (I) is 350 ppm by mass or less, and methods for producing a compound represented by formula (IV) or a salt thereof. The compound and methods have fewer impurities. The compound can be used for production of a phafflaceutical composition for therapy or prophylaxis of a disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.